Metastatic Breast Cancer Video Perspectives

Healio spoke with Nancy U. Lin, MD, about metastatic breast cancer, touching on approvals, agents in the pipeline, surveillance, survivorship and other topics impacting clinicians and patients.

In this video series, Lin, associate chief in the division of breast oncology at Susan F. Smith Center for Women's Cancers, director of the Metastatic Breast Cancer Program and the Program for Patients with Breast Cancer Brain Metastases at Dana-Farber Cancer Institute, and an associate professor of medicine at Harvard Medical School, discussed:

• practice-changing FDA approvals for metastatic breast cancer;
• interesting developments in the pipeline to keep an eye on;
• routine surveillance imaging in the early-stage setting compared with surveillance in metastatic breast cancer;
• stratifying risk for metastatic disease in early-stage breast cancer;
• the percentage of patients in the United States with de novo metastatic breast cancer and how that can inform treatment plans compared with recurrent metastatic disease;
• the role of surgery in stage IV metastatic breast cancer;
• expanding the definition of survivorship to include those living with metastatic disease;
• individualized management of metastatic breast cancer in collaboration with patients;
• “sobering” de novo breast cancer mortality data from analyses of the SEER database; and
• brain metastases in metastatic breast cancer.

Disclosure:

Lin reports receiving research support from AstraZeneca, Genentech, Merck, Pfizer, Seagen and Zion Pharmaceuticals; honoraria from Affinia Therapeutics, Aleta BioPharma, Daiichi Sankyo, Denali Therapeutics, Olema Pharmaceuticals, Pfizer, Prelude Therapeutics, Puma, Seagens and Voyager Therapeutics; and royalties from Up-to-Date.